These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 29194682)

  • 21. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
    Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
    Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    Dietz J; Kalinina OV; Vermehren J; Peiffer KH; Matschenz K; Buggisch P; Niederau C; Schattenberg JM; Müllhaupt B; Yerly S; Ringelhan M; Schmid RM; Antoni C; Müller T; Schulze Zur Wiesch J; Piecha F; Moradpour D; Deterding K; Wedemeyer H; Moreno C; Berg T; Berg CP; Zeuzem S; Welsch C; Sarrazin C;
    J Viral Hepat; 2020 Oct; 27(10):974-986. PubMed ID: 32396998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
    Sato K; Uraoka T
    World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
    Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
    New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
    Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
    Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. World-wide Prevalence of Substitutions in HCV Genome Associated With Resistance to Direct-Acting Antiviral Agents.
    Liu Z; Mao X; Wu J; Yu K; Yang Q; Suo C; Lu M; Jin L; Zhang T; Chen X
    Clin Gastroenterol Hepatol; 2021 Sep; 19(9):1906-1914.e25. PubMed ID: 31683059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs.
    Paolucci S; Premoli M; Novati S; Gulminetti R; Maserati R; Barbarini G; Sacchi P; Piralla A; Sassera D; De Marco L; Girello A; Mondelli MU; Baldanti F
    Sci Rep; 2017 Nov; 7(1):16017. PubMed ID: 29167469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.
    Cento V; Aragri M; Teti E; Polilli E; Bertoli A; Foroghi L; Barbaliscia S; Di Maio VC; Pieri A; Pace Palitti V; Sarmati L; Parruti G; Andreoni M; Perno CF; Ceccherini-Silberstein F
    J Antimicrob Chemother; 2017 Dec; 72(12):3420-3424. PubMed ID: 28961921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
    Bagaglio S; Uberti-Foppa C; Morsica G
    Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
    Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
    Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of multi-DAA resistance using a novel hepatitis C virus genotype 3a infectious culture system.
    Fernandez-Antunez C; Wang K; Fahnøe U; Mikkelsen LS; Gottwein JM; Bukh J; Ramirez S
    Hepatology; 2023 Aug; 78(2):621-636. PubMed ID: 36999539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virological patterns of HCV patients with failure to interferon-free regimens.
    Starace M; Minichini C; De Pascalis S; Macera M; Occhiello L; Messina V; Sangiovanni V; Adinolfi LE; Claar E; Precone D; Stornaiuolo G; Stanzione M; Ascione T; Caroprese M; Zampino R; Parrilli G; Gentile I; Brancaccio G; Iovinella V; Martini S; Masarone M; Fontanella L; Masiello A; Sagnelli E; Punzi R; Salomone Megna A; Santoro R; Gaeta GB; Coppola N
    J Med Virol; 2018 May; 90(5):942-950. PubMed ID: 29315640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients.
    Aldunate F; Echeverría N; Chiodi D; López P; Sánchez-Cicerón A; Fajardo A; Soñora M; Cristina J; Hernández N; Moreno P
    Dis Markers; 2018; 2018():2514901. PubMed ID: 30186532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral response and resistance analysis of treatment-naïve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256.
    Mo H; Hedskog C; Lawitz E; Brainard DM; Yang J; Delaney W; Worth A; Miller MD
    Antiviral Res; 2017 Apr; 140():151-157. PubMed ID: 28132867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance to DAAs: When to Look and When It Matters.
    Wyles DL
    Curr HIV/AIDS Rep; 2017 Dec; 14(6):229-237. PubMed ID: 29116550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey.
    Sayan M; Yıldırım FS; Akhan S; Yıldırım AA; Şirin G; Cabalak M; Demir M; Can S; Ersöz G; Altıntaş E; Ensaroğlu F; Akbulut A; Şener A; Deveci A
    Int J Infect Dis; 2020 Jun; 95():84-89. PubMed ID: 32302766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
    J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours.
    Nguyen T; Valantin MA; Delaugerre C; Amiel C; Netzer E; L'Yavanc T; Ohayon M; Valin N; Day N; Kreplak G; Pialoux G; Calvez V; Molina JM; Marcelin AG; Todesco E
    J Glob Antimicrob Resist; 2021 Mar; 24():311-315. PubMed ID: 33540082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.